title: Clinical observations on intensive immunosuppressive therapy combined with umbilical cord blood support for the treatment of severe aplastic anemia.
abstract: OBJECTIVE
  To evaluate the efficacy of enhanced, intensive, immuno-suppressive therapy with umbilical cord blood support for severe aplastic anemia (SAA).
  
  
  METHODS
  A total of 25 patients with SAA received enhanced, intensive, immuno-suppressive therapy and a cord blood transfusion. Therapy protocol: Anti-thymocyte globulin (ATG) 2.5 mg/(kg•d) × 5d; Cyclophosphamide 50 mg/(kg•d) × 2d; cyclosporin A (CsA) maintenance therapy.
  
  
  RESULTS
  25 patients were enrolled. 18 underwent a complete recovery, 4 made significant improvements, 1 did not respond, and 2 died. Therefore, the efficacy rate was 88%. The median follow-up time was 35 months (range 13-47 months), and the 3-year overall survival rate was 92%. Patients rapidly achieved reconstitution of hematopoiesis. The median time to neutrophil ANC > 0.5 × 109/L was 18 days (range 8-36), platelets >20 × 109/L was 34 days (range 12-123), and Hb > 100 g/L 95 days (range 35-173).
  
  
  CONCLUSIONS
  Enhanced, intensive, immuno-suppressive therapy with umbilical cord blood support may be an effective option for SAA therapy.
authors.forename: Fang
authors.initials: F
authors.lastname: Zhou
authors.forename: Linfu
authors.initials: L
authors.lastname: Ge
authors.forename: Zhe
authors.initials: Z
authors.lastname: Yu
authors.forename: Yuan
authors.initials: Y
authors.lastname: Fang
authors.forename: Fansheng
authors.initials: F
authors.lastname: Kong
mesh_terms: D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000097:blood / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005312:Fetal Blood / Q000637:transplantation*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents